<DOC>
	<DOCNO>NCT00510198</DOCNO>
	<brief_summary>The purpose PRECEDE-HF study collect data compare patient whose heart failure manage use Cardiac Compass OptiVol ( tool device record information heart doctor use help treat heart disease ) combine standard treatment method ( Access Group ) patient whose heart failure manage standard treatment method ( Control Group ) . This comparison show additional monitoring provide Cardiac Compass OptiVol delay time patient first admit hospital heart failure delay time death .</brief_summary>
	<brief_title>Evaluation Cardiac Compass With OptiVol Early Detection Decompensation Events Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion Criteria The following criterion apply subject : Subject CRTD dual chamber ICD Cardiac Compass OptiVol Fluid Status Monitoring implant pectoral region least 30 day prior enrollment . CRTD/ICD must support Medtronic CareLink Network . Subject marketreleased , transvenous , high voltage RV lead Subject marketreleased RA lead If subject LV lead , must compatible , Yadapted currently investigation Subject 's heart failure regimen ( i.e . beta blocker ACE inhibitor ( substitute ) unless document evidence intolerance available ) adhere current ACC/AHA guideline management chronic heart failure adult patient Subject history least one heart failure relate hospitalization , Emergency Department ( ED ) visit , urgent visit necessitate IV diuretic , IV inotropic , IV vasodilator , parenteral therapy within 12 month prior baseline evaluation Subject least 18 year age Subject willing able comply Clinical Investigation Plan ( e.g . willing able remain available followup visit , use SentryCheck , etc . ) Subject willing able transmit data use Medtronic CareLink Network Subject ( subject 's legally authorize representative ) willing able sign date study Informed Consent HIPAA Authorization ( U.S. ) Exclusion Criteria The following criterion apply subject : Subject post heart transplant actively list transplant list reasonable probability ( defined investigator ) undergo transplantation next year Subject receive coronary artery bypass graft valve surgery last 90 day Subject myocardial infarction ( MI ) last 90 day . Subject indicated valve replacement/repair Subject 's life expectancy due noncardiac reason less six month Subject serum creatinine &gt; 2.5 mg/dL measure within 30 day prior enrollment . Subject chronic renal dialysis Subject continuous intermittent ( &gt; 2 stable infusion per week ) infusion therapy HF Subject complex uncorrected congenital heart disease Subject enrol Disease Management Program outside vendor , company service employ determine , monitor , and/ alert clinician subject weight change HF sign symptom via interactive passive system Subject implant cardiac hemodynamic monitor leave ventricular assist device ( LVAD ) Subject enrol concurrent study , exception study approve Medtronic PRECEDEHF Clinical Trial Leader prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Heart Disease</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Thoracic Fluid Monitoring</keyword>
</DOC>